Is DVA a good stock to buy? We came across a bullish thesis on DaVita Inc. on StockCompass’s Substack. In this article, we will summarize the bulls’ thesis on DVA. DaVita Inc.’s share was trading at $228.03 as of July 1st. DVA’s trailing and forward P/E were 21.43 and 15.34 respectively according to Yahoo Finance.
hywards/Shutterstock.com
DaVita Inc. is one of the largest dialysis providers in the United States, serving patients with end-stage renal disease through a business model built on recurring, life-sustaining treatments that remain largely insulated from economic cycles. With an approximately 35% market share, the company benefits from a durable competitive position and stable demand, making it a defensive healthcare business capable of generating consistent cash flows regardless of broader macroeconomic conditions.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The investment thesis strengthened following an exceptional first-quarter 2026 earnings report, where DaVita exceeded earnings expectations by 23.7% and subsequently raised its full-year guidance, reinforcing confidence in its operational momentum. A central driver of the bullish case is the company’s disciplined capital allocation strategy, highlighted by the repurchase of 13.1% of its outstanding shares during fiscal 2025 and supported by a newly authorized $2 billion share buyback program.
This ongoing reduction in share count is expected to meaningfully accelerate earnings-per-share growth and enhance long-term shareholder value. Another important catalyst is the transformation of Integrated Kidney Care (IKC), which achieved its first profitable year in fiscal 2025. This milestone signals DaVita’s evolution beyond a traditional dialysis provider toward a higher-value, integrated kidney care platform, creating the potential for a meaningful market re-rating.
Despite these favorable developments, the company continues to trade at an attractive valuation of 14.2x forward adjusted earnings, offers a 9.3% free cash flow yield that exceeds historical averages, and carries a PEG ratio of just 0.40x, suggesting the market has yet to fully recognize its earnings growth potential.
Supported by recession-resistant revenues, improving profitability, aggressive share repurchases, and compelling valuation metrics, DaVita represents a high-quality compounder with significant long-term upside as its capital allocation strategy and expanding care platform continue to unlock substantial per-share value.
Previously, we covered a bullish thesis on DaVita Inc. (DVA) by Isaac459 in February 2025, which highlighted the potential recovery in dialysis treatment volumes driven by declining mortality rates. DVA’s stock price has appreciated by approximately 32.58% since our coverage. StockCompass shares a similar view but emphasizes on aggressive share repurchases, Integrated Kidney Care profitability, and per-share value creation.
DaVita Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 52 hedge fund portfolios held DVA at the end of the first quarter which was 40 in the previous quarter. While we acknowledge the risk and potential of DVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DVA and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
